Novel and Traditional Biomarkers of BoneTurnover in Postmenopausal Women
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 378869582 | ||
| 003 | CHVBK | ||
| 005 | 20180305123406.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20030127xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/CCLM.2003.013 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/CCLM.2003.013 | ||
| 245 | 0 | 0 | |a Novel and Traditional Biomarkers of BoneTurnover in Postmenopausal Women |h [Elektronische Daten] |c [Antonín Pohlídal, Petr Huek, Vladimír Palicka, David Slabík, Martin Hill, Petr Matucha] |
| 520 | 3 | |a Urinary markers of bone collagen degradation such as N-terminal telopeptide, deoxypyridinoline, hydroxyproline and proline-hydroxyproline dipeptide as a novel marker were measured in both morning and daily urine samples collected from 40 postmenopausal women on 10 consecutive days. In addition, osteocalcin, bone alkaline phosphatase and procollagen C-terminal propeptide were analyzed in one serum sample from each of the women. DXA densitometry was employed to differentiate between osteopenic and osteoporotic women. Spearman rank correlation, factor analysis and receiver-operating characteristics were computed to evaluate the results. The highest correlation with a single common factor was found between telopeptide assayed in daily urine, followed by the dipeptide and hydroxyproline assayed in morning urine. These markers also showed high sensitivity for the diagnosis of osteoporosis, while osteocalcin had a high sensitivity for the diagnosis of bone disease. The concentrations of telopeptide, dipeptide and osteocalcin differed significantly between the osteopenic and osteoporotic subjects. Because of the ease of non-hydrolyzed urine processing, the speed of chromatographic analysis and the negligible costs, the dipeptide assay opens new possibilities in the field. | |
| 540 | |a Copyright © 2003 by Walter de Gruyter GmbH & Co. KG | ||
| 690 | 7 | |a Medical equipment & techniques |2 nationallicence | |
| 690 | 7 | |a Medical diagnosis |2 nationallicence | |
| 690 | 7 | |a Diseases & disorders |2 nationallicence | |
| 700 | 1 | |a Pohlídal |D Antonín |4 aut | |
| 700 | 1 | |a Huek |D Petr |4 aut | |
| 700 | 1 | |a Palicka |D Vladimír |4 aut | |
| 700 | 1 | |a Slabík |D David |4 aut | |
| 700 | 1 | |a Hill |D Martin |4 aut | |
| 700 | 1 | |a Matucha |D Petr |4 aut | |
| 773 | 0 | |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/1(2003-01-27), 74-78 |x 1434-6621 |q 41:1<74 |1 2003 |2 41 |o cclm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2003.013 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/CCLM.2003.013 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Pohlídal |D Antonín |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Huek |D Petr |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Palicka |D Vladimír |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Slabík |D David |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hill |D Martin |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Matucha |D Petr |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/1(2003-01-27), 74-78 |x 1434-6621 |q 41:1<74 |1 2003 |2 41 |o cclm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||